drugset / Trial / NCT00239564
Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease
NaSingle-groupOpen-labelTreatment
Summary
The objective is to compare the pharmacokinetics and pharmacodynamics of IPX054 and carbidopa-levodopa immediate-release tablets in subjects with idiopathic Parkinson's disease who are currently being treated with a stable regimen of carbidopa-levodopa immediate-release tablets.
Timeline
- Start
- 2005-10
- Primary completion
- 2007-12
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carbidopa | Unknown | 25 mg | — |
| Subject | Carbidopa | Unknown | 37.5 mg | — |
| Subject | Carbidopa | Unknown | 50 mg | — |
| Subject | Carbidopa | Unknown | 62.5 mg | — |
| Subject | Carbidopa | Unknown | 75 mg | — |
| Subject | Levodopa | Unknown | 100 mg | — |
| Subject | Levodopa | Unknown | 150 mg | — |
| Subject | Levodopa | Unknown | 200 mg | — |
| Subject | Levodopa | Unknown | 250 mg | — |
| Subject | Levodopa | Unknown | 300 mg | — |